FDA's Revised CDS Guidance and Enforcement Discretion
Key Questions
What does the FDA's revised CDS guidance clarify?
It clarifies non-device criteria and enforcement discretion for single-recommendation clinical decision support tools. This reduces FDA premarket review for certain CDS software.
How has the EHRA responded to the FDA's CDS updates?
EHRA praises the tech-neutral approach but raises concerns about overreach on automation bias and time-criticality. The changes remove a prior quality proxy for AI tool buyers.
What implications does the guidance have for AI evaluation?
Without FDA premarket review, buyers must independently assess CDS tools. This shifts diligence responsibility away from regulatory oversight.
Which articles discuss the FDA's CDS guidance in detail?
Related coverage includes the FDA's own CDS page, analysis on reduced regulation and buyer burden, and EHRA's perspective for EHR developers.
What is the current status of this FDA guidance topic?
The highlight is marked as developing, indicating ongoing regulatory evolution and interpretation.
FDA's updated CDS guidance clarifies non-device criteria and enforcement discretion for single-recommendation tools. EHRA praises tech-neutrality but flags overreach on automation bias and time-criticality. This shift removes a quality proxy for buyers, raising questions about AI evaluation without FDA premarket review. Status: developing.